[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641914":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":32,"responsibleParty":45,"collaborators":20,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":20,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":20,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":35,"whyStopped":20,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Marmara University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"taVNS Group","EXPERIMENTAL","Participants with psoriatic arthritis will receive transcutaneous auricular vagus nerve stimulation (taVNS) using the Vagustim device. Electrical stimulation will be applied through electrodes placed on the tragus and cymba conchae regions of the auricle for 20 minutes per session over a 10-day treatment period.",[13],"Device: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)","Non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) will be administered using the Vagustim device. Electrodes will be placed on the tragus and cymba conchae regions of the auricle, which are anatomically associated with the auricular branch of the vagus nerve. Electrical stimulation will be applied for 20 minutes per session over a 10-day treatment period while participants are in a seated position. All procedures will be performed according to standardized stimulation parameters and patient safety protocols.",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Halise Hande Gezer, MD, Associate Professor","Marmara University Faculty of Medicine","PRINCIPAL_INVESTIGATOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"Zeynep M Kurt, MD","CONTACT","+90 533 485 59 11","kurtzeynepmelis@gmail.com",[33],{"facility":34,"status":35,"city":36,"state":20,"zip":37,"country":38,"countryCode":20,"cosmosGeoPoint":39,"geoPoint":44,"contacts":20},"Marmara University Pendik Training and Research Hospital","RECRUITING","Istanbul","34899","Turkey (Türkiye)",{"type":40,"coordinates":41},"Point",[42,43],28.94966,41.01384,{"lat":43,"lon":42},{"type":46,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100641914","transcutaneous-auricular-vagus-nerve-stimulation-in-psoriatic-arthritis-100641914",false,"NCT07653009","Transcutaneous Auricular Vagus Nerve Stimulation in Psoriatic Arthritis","The Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Disease Activity and Related Clinical Parameters in Patients With Psoriatic Arthritis","Inclusion Criteria:\n\n* Diagnosis of psoriatic arthritis according to the CASPAR criteria\n* Age between 18 and 65 years\n* Stable treatment regimen for at least 12 weeks prior to enrollment\n* Visual Analog Scale (VAS) pain score ≥4 on a 0-10 scale\n* Moderate-to-high disease activity according to the Disease Activity Index for Psoriatic Arthritis (DAPSA)\n* Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Presence of an implanted cardiac device (e.g., pacemaker, implantable cardioverter-defibrillator) or implanted neurostimulator\n* History of epilepsy or other uncontrolled neurological disorders\n* Active severe infection or immunosuppressive condition (e.g., sepsis)\n* Pregnancy or breastfeeding\n* Presence of deep auricular injury, previous ear surgery, or active skin lesions involving the auricle\n* Inability to comply with the treatment protocol or history of severe psychiatric disorders","ALL","18 Years","65 Years",{"count":58,"type":59},15,"ESTIMATED","INTERVENTIONAL",[62],"NA","This prospective single-center interventional study aims to investigate the effects of transcutaneous auricular vagus nerve stimulation (taVNS) on disease activity, pain, quality of life, autonomic dysfunction symptoms, and inflammatory biomarkers in patients with psoriatic arthritis (PsA). Participants diagnosed with PsA according to the Classification Criteria for Psoriatic Arthritis (CASPAR) will undergo non-invasive auricular vagus nerve stimulation using the Vagustim device. Clinical outcomes including the Disease Activity Index for Psoriatic Arthritis (DAPSA), Ankylosing Spondylitis Disease Activity Score based on C-reactive protein (ASDAS-CRP), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), pain scores, sleep quality, quality of life, anxiety\u002Fdepression, and inflammatory markers including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) will be evaluated before and after treatment.",[65],"Psoriatic Arthritis",[67,68,69],"Transcutaneous Auricular Vagus Nerve Stimulation","Vagus Nerve Stimulation","Autonomic Dysfunction Disease Activity","2026-06-11",{"date":72,"type":73},"2026-06-17","ACTUAL",{"date":75,"type":73},"2026-06-02",{"date":77,"type":59},"2027-08-02",{"name":5,"class":6},1]